UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


                                 March 21, 2006
                        (Date of earliest event reported)


                             Innovate Oncology, Inc.
             (Exact name of registrant as specified in its charter)


         Nevada                     33-55254-28                  87-0438641
(State of Incorporation)      (Commission File Number)         (IRS Employer
                                                             Identification No.)


                 712 Fifth Avenue, 19th Floor New York, NY 10019
                    (Address of principal executive offices)

                                  646-723-8944
                     (Telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[_]   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425

[_]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12

[_]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

[_]   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

Section 5 Corporate Governance and Management

Item 5.02 Departure of Directors or Principal Officers: Election of Directors;
Appointment of Principal Officers

(b) By mutual agreement, Dr. Frank Armstrong resigned as a member of the Board
of Directors effective on March 21, 2006. His resignation is not related to any
disagreement with the Company.



<PAGE>



                                   Signatures


Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                            Innovate Oncology, Inc.
                                              (Registrant)


                                            /s/ Paul Hopper
                                            ----------------------------------
                                            Paul Hopper
                                            Chief Executive Officer

                                            March 24, 2006
{"company-data": {"conformed-name": "INNOVATE ONCOLOGY, INC.", "cik": "0000894538", "assigned-sic": "9995", "irs-number": "870438641", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "033-55254-28", "film-number": "06710035"}, "business-address": {"street1": "712 FIFTH AVENUE", "street2": "19TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10019", "phone": "646 723 8944"}, "mail-address": {"street1": "712 FIFTH AVENUE", "street2": "19TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10019"}, "former-company": [{"former-conformed-name": "HAMPTON BERKSHIRE INSURANCE & FINANCIAL INC", "date-changed": "20030318"}, {"former-conformed-name": "FIRST CAPITAL RESOURCES COM INC", "date-changed": "19990512"}, {"former-conformed-name": "JACKAL INDUSTRIES INC", "date-changed": "19940706"}]}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                                 March 21, 2006
                        (Date of earliest event reported)

                             Innovate Oncology, Inc.
             (Exact name of registrant as specified in its charter)

         Nevada                     33-55254-28                  87-0438641
(State of Incorporation)      (Commission File Number)         (IRS Employer
                                                             Identification No.)

                 712 Fifth Avenue, 19th Floor New York, NY 10019
                    (Address of principal executive offices)

                                  646-723-8944
                     (Telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[_]   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425

[_]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12

[_]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

[_]   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

Section 5 Corporate Governance and Management

Item 5.02 Departure of Directors or Principal Officers: Election of Directors;
Appointment of Principal Officers

(b) By mutual agreement, Dr. Frank Armstrong resigned as a member of the Board
of Directors effective on March 21, 2006. His resignation is not related to any
disagreement with the Company.
Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                            Innovate Oncology, Inc.
                                              (Registrant)

                                            /s/ Paul Hopper
                                            ----------------------------------
                                            Paul Hopper
                                            Chief Executive Officer

                                            March 24, 2006